Abstract
Two children with Guillain-Barrè syndrome were succesfully treated with high-dose intravenous immunoglobulin (IVIG) and no relapses occurred over a 1 year follow up. No side-effects were observed. These data provide further evidence that IVIG may be safely and effectively employed in children with Guillain-Barrè syndrome.
Original language | English |
---|---|
Pages (from-to) | 372-374 |
Number of pages | 3 |
Journal | European Journal of Pediatrics |
Volume | 152 |
Issue number | 4 |
DOIs | |
Publication status | Published - Apr 1993 |
Keywords
- Guillain-Barrè syndrome
- Intravenous immunoglobulin
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health